阿托伐他汀对2型糖尿病患者CRP的影响

1. Kannel WB.McGee DL Diabetes and cardiovascular disease.The Framingham study 1979
2. Ridker PM Clinical application of C - reactive protein for cardiovascular disease detection and prevention 2003
3. Freeman DJ.Nome J.Caslake MJ C - reactive protein is an inde - pendent predictor of risk for the development of diabetes in the west of Scotland coronary prevention study 2002
4. Hu FB.Meigs JB.Li TY Inflammatory markers and risk of developing type 2 diabetes in women 2004(3)
5. Mueck A O.Seeger H Statins and direct vascular actions 2003(1)
6. Festa A.D'Agostino R.Howard G Chronic subclinical inflammation as part of the insulin resistance syndrome:the Insulin Resistance Atherosclerosis Study (IRAS) 2000
7. Colhoun HM.Betteridge DJ.Durrington PN Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo - controlled trial 2004(9435)
8. Ridker PM Clinical application of C - reactive protein for cardiovascular disease detection and prevention 2003
9. Pickup JC.Mattock MB.Chusney GD NIDDM as a disease of the innate immune system:association of acute - phase reaction and inter -leukin-6 with metabolic syndrome X 1997
10. Ridker PM.Rifai N.Pfeifer MA.Sacks F,Braunwald E for the Cholesterol and Recurrent Events (CARE) Investigators.Long - term effects of pravastatin on plasma concentration of C - reactive protein 1999
11. van de Ree MA.Huisman MV.Princen HM Strong decrease of high sensitivity C - reactive protein with high - dose atorvastatin in patients with type 2 diabetes mellitus 2003(1)

更多...